Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Am J Kidney Dis. 2015 May 2;66(1):106–113. doi: 10.1053/j.ajkd.2015.02.339

Figure 2. Actual Treatment Received Among Patients in Darbepoetin Alfa versus Epoetin Alfa Facilities, by Month of Follow-up.

Figure 2

Upper panels show the percentages of prevalent hemodialysis patients with Medicare Parts A+B who received darbepoetin alfa (DPO) versus epoetin alfa (EPO) versus both in each calendar month; Lower panels show the percentages of incident hemodialysis patients with Medicare Parts A+B who received darbepoetin alfa versus epoetin alfa versus both in each calendar month (corresponds to cohort studies for nonfatal outcomes). Left panels are darbepoetin alfa facilities, right panels are epoetin alfa facilities. MPAB – Medicare primary payor, Parts A+B.